Drugs.com - Clinical Trials

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the...

Jun 5, 2025 - 01:35
 0
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the...
Read More

Tags:

Previous Article

Ciao, Bella: Road Tripping with the Alfa Romeo Stelvio Tributo Italiano

Next Article

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trime...

Related Posts

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presented New Data From Pivotal Phase 3 IMPALA-2...

May 26, 2025  0

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Rilzabrutinib Granted Orphan Drug Designation in the US...

May 12, 2025  0

Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial

Bristol Myers Squibb Provides Update on Camzyos Phase 3...

May 12, 2025  0